PI3K signaling: A crossroads of metabolic regulation

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 4, 2009, Pages 349-357

  Braccini, Laura ^a   Ciraolo, Elisa ^a   Morello, Fulvio ^a   Lu, Xiaoyun ^a   Hirsch, Emilio ^a  

^a Molecular Biotechnology Center   (Italy)

Author keywords

Diabetes; Insulin; Phosphoinositide 3 kinase

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE SIGMA; PROTEIN KINASE B; PROTEIN P110; PROTEIN P85; UNCLASSIFIED DRUG;

CELL FUNCTION; DISEASE COURSE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ANALYSIS; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 69949128583     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.19     Document Type: Review

References (71)

1. Foukas LC, Claret M, Pearce W et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091), 366-370 (2006).
2. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110[α] in insulin signaling. Cell 125(4), 733-747 (2006).
3. Pirola L, Zvelebil MJ, Bulgarelli-Leva G et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα). Functions of lipid kinase-deficient PI3Kα in signaling. J. Biol. Chem. 276(24), 21544-21554 (2001).
4. Ciraolo E, Iezzi M, Marone R et al. Phosphoinositide 3-kinase p110{β} activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1(36), RA3 (2008).
5. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008).
6. Braccini L, Morello F, Perino A, Hirsch E. Post-wortmannin era: novel phosphoinositide 3-kinase inhibitors with potential therapeutic applications. Curr. Enzyme Inhibition (2009) (In Press).
7. Iida S, Ono A, Sayama K et al. Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/MMAC1 gene. Anticancer Res. 20(3B), 1901-1904 (2000).
8. Ooms LM, Horan KA, Rahman P et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem. J. 419(1), 29-49 (2009).
9. Kaisaki PJ, Delepine M, Woon PY et al. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes 53(7), 1900-1904 (2004).
10. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. Two new substrates in insulin signaling IRS5/DOK4 and IRS6/DOK5. J. Biol. Chem. 278(28), 25323-25330 (2003).
11. Sun XJ, Pons S, Wang LM et al. The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol. Endocrinol. 11(2), 251-262 (1997).
12. Araki E, Sun XJ, Haag BL 3rd et al. Human skeletal muscle insulin receptor substrate-1. Characterization of the cDNA, gene, and chromosomal localization. Diabetes 42(7), 1041-1054 (1993).
13. Sciacchitano S, Taylor SI. Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene. Endocrinology 138(11), 4931-4940 (1997).
14. Schreyer S, Ledwig D, Rakatzi I, Kloting I, Eckel J. Insulin receptor substrate-4 is expressed in muscle tissue without acting as a substrate for the insulin receptor. Endocrinology 144(4), 1211-1218 (2003).
15. Alessi DR, Downes CP The role of PI 3-kinase in insulin action. Biochim. Biophys. Acta 1436(1-2), 151-164 (1998).
16. Asano T, Kanda A, Katagiri H et al. p110β is is up-regulated during differentiation of 3T3-L1 cells and contributes to the highly insulin-responsive glucose transport activity. J. Biol. Chem. 275(23), 17671-17676 (2000).
17. Beeson M, Sajan MP, Dizon M et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 52(8), 1926-1934 (2003).
18. Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am. J. Physiol. Endocrinol. Metab. 295(1), E29-E37 (2008).
19. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559), 785-789 (1995).
20. McManus EJ, Sakamoto K, Armit LJ et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24(8), 1571-1583 (2005).
21. Lee AD, Hansen PA, Holloszy JO. Wortmannin inhibits insulin-stimulated but not contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett. 361(1), 51-54 (1995).
22. Shepherd PR, Nave BT, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem. J. 305(Pt 1), 25-28 (1995).
23. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase. Mamm. Genome 13(3), 169-172 (2002).
24. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274(16), 10963-10968 (1999).
25. Wang Q, Bilan PJ, Tsakiridis T, Hinek A, Klip A. Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Biochem. J. 331 (Pt 3), 917-928 (1998).
26. Jia S, Liu Z, Zhang S et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454(7205), 776-779 (2008).
27. Maffucci T, Brancaccio A, Piccolo E, Stein RC, Falasca M. Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J. 22(16), 4178-4189 (2003).
28. Chaussade C, Pirola L, Bonnafous S et al. Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol. Endocrinol. 17(12), 2448-2460 (2003).
29. Domin J, Pages F, Volinia S et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326(Pt 1), 139-147 (1997).
30. Arcaro A, Volinia S, Zvelebil MJ et al. Human phosphoinositide 3-kinase C2β, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem. 273(49), 33082-33090 (1998).
31. Ono F, Nakagawa T, Saito S et al. A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J. Biol. Chem. 273(13), 7731-7736 (1998).
32. Brown RA, Domin J, Arcaro A, Waterfield MD, Shepherd PR. Insulin activates the α isoform of class II phosphoinositide 3-kinase. J. Biol. Chem. 274(21), 14529-14532 (1999).
33. Brown RA, Shepherd PR. Growth factor regulation of the novel class II phosphoinositide 3-kinases. Biochem. Soc. Trans. 29(Pt 4), 535-537 (2001).
34. Arcaro A, Zvelebil MJ, Wallasch C et al. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol. 20(11), 3817-3830 (2000).
35. Falasca M, Hughes WE, Dominguez V et al. The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem. 282(38), 28226-28236 (2007).
36. Christoforidis S, Miaczynska M, Ashman K et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol. 1(4), 249-252 (1999).
37. Soos MA, Jensen J, Brown RA et al. Class II phosphoinositide 3-kinase is activated by insulin but not by contraction in skeletal muscle. Arch. Biochem. Biophys. 396(2), 244-248 (2001).
38. Daimon M, Sato H, Oizumi T et al. Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese population. Biochem. Biophys. Res. Commun. 365(3), 466-471 (2008).
39. Berwick DC, Dell GC, Welsh GI et al. Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. J. Cell Sci. 117(Pt 25), 5985-5993 (2004).
40. Ikonomov OC, Sbrissa D, Shisheva A. YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes. Biochem. Biophys. Res. Commun. 382(3), 566-570 (2009).
41. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. β-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord. 9(4), 329-343 (2008).
42. Fruman DA, Mauvais-Jarvis F, Pollard DA et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 α. Nat. Genet. 26(3), 379-382 (2000).
43. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor - mTOR complex. Science 307(5712), 1098-1101 (2005).
44. Pende M, Kozma SC, Jaquet M et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature 408(6815), 994-997 (2000).
45. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98(20), 11598-11603 (2001).
46. Dickson LM, Rhodes CJ. Pancreatic β-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am. J. Physiol. Endocrinol. Metab. 287(2), E192-E198 (2004).
47. Withers DJ, Gutierrez JS, Towery H et al. Disruption of IRS-2 causes Type 2 diabetes in mice. Nature 391(6670), 900-904 (1998).
48. Tamemoto H, Kadowaki T, Tobe K et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372(6502), 182-186 (1994).
49. Araki E, Lipes MA, Patti ME et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372(6502), 186-190 (1994).
50. -/- double knockout mice. Genes Dev. 16(24), 3213-3222 (2002).
51. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J. Clin. Invest. 97(11), 2569-2575 (1996).
52. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 3(6), 393-402 (2006).
53. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25(5), 1596-1607 (2005).
54. Chaussade C, Rewcastle GW, Kendall JD et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J. 404(3), 449-458 (2007).
55. Le Stunff C, Dechartres A, Mariot V et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes 57(2), 494-502 (2008).
56. Ozanne SE, Jensen CB, Tingey KJ et al. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia 48(3), 547-552 (2005).
57. Terauchi Y, Tsuji Y, Satoh S et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 α subunit of phosphoinositide 3-kinase. Nat. Genet. 21(2), 230-235 (1999).
58. Mauvais-Jarvis F, Ueki K, Fruman DA et al. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J. Clin. Invest. 109(1), 141-149 (2002).
59. Chen D, Mauvais-Jarvis F, Bluher M et al. p50α/p55α phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell. Biol. 24(1), 320-329 (2004).
60. Ueki K, Fruman DA, Yballe CM et al. Positive and negative roles of p85 α and p85 β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J. Biol. Chem. 278(48), 48453-48466 (2003).
61. Ueki K, Yballe CM, Brachmann SM et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 99(1), 419-424 (2002).
62. Taniguchi CM, Tran TT, Kondo T et al. Phosphoinositide 3-kinase regulatory subunit p85α suppresses insulin action via positive regulation of PTEN. Proc. Natl Acad. Sci. USA 103(32), 12093-12097 (2006).
63. Taniguchi CM, Kondo T, Sajan M et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metab. 3(5), 343-353 (2006).
64. Kurlawalla-Martinez C, Stiles B, Wang Y et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol. Cell. Biol. 25(6), 2498-2510 (2005).
65. Ueki K, Fruman DA, Brachmann SM et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 22(3), 965-977 (2002).
66. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54(8), 2351-2359 (2005).
67. Baynes KC, Beeton CA, Panayotou G et al. Natural variants of human p85 α phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity. Diabetologia 43(3), 321-331 (2000).
68. George S, Rochford JJ, Wolfrum C et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304(5675), 1325-1328 (2004).
69. Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292(5522), 1728-1731 (2001).
70. Garofalo RS, Orena SJ, Rafidi K et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB β. J. Clin. Invest. 112(2), 197-208 (2003).
71. Sun S-Y, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65(16), 7052-7058 (2005).